No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

PURPOSE: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Kyong, Hwang, Jun Gi, Park, Min Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089085/
https://www.ncbi.nlm.nih.gov/pubmed/33953542
http://dx.doi.org/10.2147/DDDT.S302215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089085/
https://www.ncbi.nlm.nih.gov/pubmed/33953542
http://dx.doi.org/10.2147/DDDT.S302215

Ejemplares similares